Celyad (CYAD) Received its Third Buy in a Row


After William Blair and Piper Jaffray gave Celyad (NASDAQ: CYAD) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Edward White maintained a Buy rating on Celyad today and set a price target of $46. The company’s shares closed yesterday at $28.

White noted:

“We base our $46 price target on probability-adjusted revenue forecasts for CYAD-01 in r/r AML and third line metastatic CRC. We use the net present value of our revenue forecast through 2026, apply a 25% POS for AML and 20% POS for CRC, a 4x price/sales multiple. We include our year-end 2018 estimated fully diluted net cash of $4.39/share (assuming €1.00 = $1.15) to arrive at our price target. Our P/S multiple of 4x is in-line with Celyad’s peers that range between 2-5x.”

According to TipRanks.com, White is a 5-star analyst with an average return of 14.0% and a 43.9% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.

Celyad has an analyst consensus of Strong Buy, with a price target consensus of $48.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $48.20 and a one-year low of $22.17. Currently, Celyad has an average volume of 6,982.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Celyad SA is a clinical-stage biopharmaceutical company, which engages in the identification and development of specialized cell-based therapies. Its products include cardiopoiesis platform, immuno-oncology, and medical devices. The company was founded by Michel Lussier and William Wijns on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts